Stock AnalizAbCellera Biologics Inc. ABCL
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
AbCellera Biologics Inc. (ABCL) is a healthcare company listed in the US with a market value of about $3.8B. In the twelve months to September 30, 2026 it had revenue of $68M and net income of -$148M, a net margin of -218.5%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -20% a year, a 5-year average ROIC of -6%.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $68M | $75M | $29M | $38M | $485M | $375M | $233M | $12M |
| Net income | -$148M | -$146M | -$163M | -$146M | $159M | $153M | $119M | -$2M |
| Free cash flow | -$33M | -$174M | -$187M | -$121M | $207M | $186M | $13M | -$1M |
| EPS (diluted) | $-0.48 | $-0.49 | $-0.55 | $-0.51 | $0.50 | $0.48 | $0.45 | $-0.01 |
| Net margin | -218.5% | -194.9% | -564.8% | -385.0% | 32.7% | 40.9% | 51.0% | -19.0% |
| ROIC | — | -16.1% | -22.8% | -16.2% | 10.9% | 13.4% | 14.1% | -31.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $18.00, 57% above the current price; targets range from $12.00 to $30.00; the consensus rating is “Strong buy”; expected EPS is $-0.60 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does AbCellera Biologics pay a dividend?
Not currently.
Is AbCellera Biologics a good stock to buy?
We do not give buy or sell advice. AbCellera Biologics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.